Evidence map›Paper›PMID 35851093›Full record

ArticleCancer & metabolism2022

Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity.

Daniela D Weber, Sepideh Aminzadeh-Gohari, Maheshwor Thapa, Anna-Sophia Redtenbacher, Luca Catalano, Tânia Capelôa, Thibaut Vazeille, Michael Emberger, Thomas K Felder, René G Feichtinger and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancer & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Dietary restriction in senolysis and prevention and treatment of disease.Critical reviews in food science and nutrition · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Daniela D Weber *Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Sepideh Aminzadeh-Gohari *Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Maheshwor ThapaBiocrates Life Sciences AG, 6020, Innsbruck, Austria.
Anna-Sophia RedtenbacherResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Luca CatalanoResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Tânia CapelôaInstitut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 1200, Brussels, Belgium.
Thibaut VazeilleInstitut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 1200, Brussels, Belgium.
Michael EmbergerPatholab Salzburg, 5020, Salzburg, Austria.
Thomas K FelderDepartment of Laboratory Medicine, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
René G FeichtingerResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Peter KoelblingerDepartment of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Guido DallmannBiocrates Life Sciences AG, 6020, Innsbruck, Austria.
Pierre SonveauxInstitut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 1200, Brussels, Belgium.
Roland LangDepartment of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria. r.lang@salk.at.
Barbara KoflerResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria. b.kofler@salk.at.
Paracelsus Medical University · ATUCLouvain · BEBiocrates Life Sciences (Austria) · AT

Funding

Austrian Science Fund FWF P 31228
6 · The paper itself

Abstract

backgroundGrowing evidence supports the use of low-carbohydrate/high-fat ketogenic diets as an adjunctive cancer therapy. However, it is unclear which genetic, metabolic, or immunological factors contribute to the beneficial effect of ketogenic diets. Therefore, we investigated the effect of ketogenic diets on the progression and metabolism of genetically and metabolically heterogeneous melanoma xenografts, as well as on the development of melanoma metastases in mice with a functional immune system.

methodsMice bearing BRAF mutant, NRAS mutant, and wild-type melanoma xenografts as well as mice bearing highly metastatic melanoma allografts were fed with a control diet or ketogenic diets, differing in their triglyceride composition, to evaluate the effect of ketogenic diets on tumor growth and metastasis. We performed an in-depth targeted metabolomics analysis in plasma and xenografts to elucidate potential antitumor mechanisms in vivo.

resultsWe show that ketogenic diets effectively reduced tumor growth in immunocompromised mice bearing genetically and metabolically heterogeneous human melanoma xenografts. Furthermore, the ketogenic diets exerted a metastasis-reducing effect in the immunocompetent syngeneic melanoma mouse model. Targeted analysis of plasma and tumor metabolomes revealed that ketogenic diets induced distinct changes in amino acid metabolism. Interestingly, ketogenic diets reduced the levels of alpha-amino adipic acid, a biomarker of cancer, in circulation to levels observed in tumor-free mice. Additionally, alpha-amino adipic acid was reduced in xenografts by ketogenic diets. Moreover, the ketogenic diets increased sphingomyelin levels in plasma and the hydroxylation of sphingomyelins and acylcarnitines in tumors.

conclusionsKetogenic diets induced antitumor effects toward melanoma regardless of the tumors´ genetic background, its metabolic signature, and the host immune status. Moreover, ketogenic diets simultaneously affected multiple metabolic pathways to create an unfavorable environment for melanoma cell proliferation, supporting their potential as a complementary nutritional approach to melanoma therapy.

Indexed as

Cancer metabolismKetogenic dietMelanomaMetabolomics

Identifiers

PMID35851093
PMCPMC9290281
OpenAlexW4285728898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.